scholarly journals Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic  -Cell Mass and Function in a Rodent Model of Type 2 Diabetes

Diabetes ◽  
2006 ◽  
Vol 55 (6) ◽  
pp. 1695-1704 ◽  
Author(s):  
J. Mu ◽  
J. Woods ◽  
Y.-P. Zhou ◽  
R. S. Roy ◽  
Z. Li ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cell Mass ◽  
Dipeptidyl Peptidase ◽  
Rodent Model ◽  
Pancreatic Cell ◽  
Dipeptidyl Peptidase 4 ◽  
And Function

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

2009 ◽  
Vol 623 (1-3) ◽  
pp. 148-154 ◽  
Author(s):  
James Mu ◽  
Aleksandr Petrov ◽  
George J. Eiermann ◽  
John Woods ◽  
Yun-Ping Zhou ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Islet Cell ◽  
Cell Mass ◽  
Rodent Model ◽  
And Function

Dipeptidyl Peptidase-4 Inhibitors and the Management of Hyperglycemia

2009 ◽  
Vol 05 (01) ◽  
pp. 63
Author(s):  
Pamela M Katz ◽  
Lawrence A Leiter ◽  
◽  
Keyword(s):  
Type 2 Diabetes ◽  
Cell Mass ◽  
Beta Cell Mass ◽  
Dipeptidyl Peptidase ◽  
Minimal Risk ◽  
Triple Combination Therapy ◽  
Dipeptidyl Peptidase 4 ◽  
Oral Antihyperglycemic Agents ◽  
Dipeptidyl Peptidase 4 Inhibitors

Incretin-based therapies, including both glucagon-like peptide 1 (GLP-1) analogs and dipeptidyl peptidase-4 (DPP-4) inhibitors, are increasingly being used for the treatment of type 2 diabetes. GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are gut-derived incretin hormones that regulate glucose through co-ordinated effects on pancreatic alpha and beta cells. DPP-4 inhibitors enhance the effects of endogenous, active GLP-1 and GIP by inhibiting the enzyme responsible for their degradation. These agents lower glycated hemoglobin (HbA1c) and help patients achieve glycemic targets, yet are weight-neutral and, due to their glucose-dependant mechanism of action, carry minimal risk of hypoglycemia. Furthermore, incretin-based therapies may alter disease progression through preservation of beta-cell mass and function. Although initially recommended for use in the early stages of type 2 diabetes, DPP-4 inhibitors appear to maintain their glycemic efficacy across the continuum of disease. They can be used either as monotherapy or in dual or triple combination therapy with other oral antihyperglycemic agents, and potentially also in combination with insulin. This review will focus on DPP-4 inhibitors and current clinical trial evidence to support their use in the management of hyperglycemia in type 2 diabetes.

Soluble dipeptidyl peptidase-4 activity is associated with decreased renal function in patients with type 2 diabetes

2018 ◽  
Author(s):  
Eun-Hee Cho ◽  
Ji Yun Jeong ◽  
Mi Young Lee ◽  
Jung Min Kim ◽  
Mi-Seon Shin
Keyword(s):  
Type 2 Diabetes ◽  
Renal Function ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4

scholarly journals Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review

2021 ◽  
Author(s):  
Mutiu Kazeem ◽  
Habeeb Bankole ◽  
Olabisi Ogunrinola ◽  
Adedoja Wusu ◽  
Abidemi Kappo
Keyword(s):  
Type 2 Diabetes ◽  
Functional Foods ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Inhibitory Potential

scholarly journals SAT0583 DIPEPTIDYL PEPTIDASE-4 AND RISK OF PSORIASIS IN PATIENTS WITH TYPE 2 DIABETES

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1250.2-1251
Author(s):  
W. S. Chen ◽  
Y. S. Chang ◽  
C. Y. Tsai ◽  
C. C. Chang
Keyword(s):  
Type 2 Diabetes ◽  
Propensity Score ◽  
Combination Therapy ◽  
Group Versus ◽  
Dipeptidyl Peptidase ◽  
Matched Pair ◽  
Diabetic Patients ◽  
Research Database ◽  
Dipeptidyl Peptidase 4

Background:The risk of psoriasis in diabetic patients has rarely been explored.Objectives:This study aimed to investigate the association between dipeptidyl peptidase-4 (DPP4) inhibitors and the risk of psoriasis in type 2 diabetes mellitus (T2DM) patients.Methods:We conducted a population-based propensity score-matched cohort study on the basis of Taiwan’s National Health Insurance Research Database that included initiators of combination therapy with DPP4i (DPP4i plus metformin) and sulfonylurea (sulfonylurea plus metformin). Psoriasis (PSO) was identified with ≥2 diagnoses. Diabetes complications severity index (DCSI) was calculated. A total of 22721 DPP4 initiator and 227684 sulfonylurea initiator were identified. A 1:10 matched-pair cohort based on propensity score(PS) was created. PS-stratified Cox proportional hazards models compared the risk of PSO in DPP4i versus sulfonylurea initiator within 2 years, controlling for potential confounders.Results:After propensity score matching, 9962 patients with T2DM starting DPP4i combination therapy and 39848 starting sulfonylurea combination therapy were selected. The incidence rate of PSO was lower in DPP4i group (188/100000 person- years) than in sulfonylurea group (467/100000 person-years). Risks of incident psoriasis were significantly lower in the DPP4i group versus sulfonylurea with the PS-stratified HR of 0.422 (95% CI 0.273 to 0.716).Conclusion:DPP4i plus metformin was associated with a reduced risk of psoriasis than sulfonylurea plus metformin. These findings merit further investigation.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document